Loading organizations...
§ Private Profile · Leichhardt, New South Wales, Australia
MedTech company developing AI-guided wearable sensors for maternal and fetal health, monitoring pregnancy and preventing postpartum hemorrhage.
Founded in 2013 by Dr. Sarah McDonald, Baymatob is a medical technology company based in Leichhardt, New South Wales, developing an AI-guided wearable sensor and diagnostics platform to monitor maternal and fetal health. Led by CEO Tara Croft, the firm's flagship device, Oli, utilizes non-invasive technology to predict severe complications like postpartum hemorrhage, earning an FDA Breakthrough Device Designation in 2021. Operating with a team of 22 employees, the pre-commercial enterprise generates under $5 million in revenue while navigating regulatory approvals and clinical trials. To advance commercialization, Baymatob raised $4.215 million in Series A funding from prominent investors including Scale Investors, Australian Unity’s Future of Healthcare Fund, and Global Bio Fund. The company is currently conducting an international clinical trial enrolling over 130 patients in partnership with Woman’s Hospital, marking its first site in the United States.
Baymatob has raised $4.2M across 1 funding round.
Baymatob has raised $4.2M in total across 1 funding round.
Baymatob has raised $4.2M in total across 1 funding round.
Baymatob's investors include Alberts Impact Ventures, Australian Unity, Global Bio Fund.
Baymatob has raised $4.2M across 1 funding round. Most recently, it raised $4.2M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 24, 2022 | $4.2M Series A | — | Alberts Impact Ventures, Australian Unity, Global BIO Fund | Announced |